Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.76 USD
Change Today +0.32 / 3.07%
Volume 971.8K
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (FOLD) Snapshot

Open
$10.38
Previous Close
$10.44
Day High
$10.88
Day Low
$10.32
52 Week High
03/19/15 - $13.20
52 Week Low
05/8/14 - $1.92
Market Cap
1.0B
Average Volume 10 Days
1.5M
EPS TTM
$-0.93
Shares Outstanding
96.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMICUS THERAPEUTICS INC (FOLD)

amicus therapeutics inc (FOLD) Related Bloomberg News

View More Bloomberg News

amicus therapeutics inc (FOLD) Related Businessweek News

No Related Businessweek News Found

amicus therapeutics inc (FOLD) Details

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company’s development programs include next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I. It also develops pharmacological chaperone migalastat HCl as a monotherapy that has completed two Phase III global registration studies for Fabry disease; ATB200, a recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for the treatment of Parkinson's disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

97 Employees
Last Reported Date: 03/3/15
Founded in 2002

amicus therapeutics inc (FOLD) Top Compensated Officers

Chairman and Chief Executive officer
Total Annual Compensation: $1.1M
President and Chief Operating Officer
Total Annual Compensation: $635.0K
Chief Financial Officer and Secretary
Total Annual Compensation: $568.6K
Chief Medical Officer
Total Annual Compensation: $707.1K
Vice President of Legal & Intellectual Proper...
Total Annual Compensation: $418.2K
Compensation as of Fiscal Year 2014.

amicus therapeutics inc (FOLD) Key Developments

Amicus Therapeutics, Inc. Proposes Amendments to Restated Certificate of Incorporation

Amicus Therapeutics, Inc. proposed an amendment to restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01 per share, that are authorized to issue from 125,000,000 shares to 250,000,000 shares, to its 2015 annual meeting of stockholders to be held on June 10, 2015.

Amicus Therapeutics Appoints David Allsop as Senior Vice President, International

Amicus Therapeutics has appointed David Allsop as Senior Vice President, International, effective April 27, 2015. He will be responsible for Amicus' international organizational build out, and will lead international commercial and market access activities for migalastat monotherapy for Fabry disease. Mr. Allsop will serve as a member of the Amicus executive team reporting to Bradley L. Campbell, President and Chief Operating Officer. Prior to joining Amicus, Mr. Allsop was instrumental in building Biogen's international commercial organization over the last 17 years. He most recently served as Senior Vice President, Europe and Canada, with full responsibility for the business and organization in those territories. While at Biogen he led the successful international launch of several products in the multiple sclerosis franchise, including Avonex, Tysabri, Fampyra, Tecfidera and Plegridy as well as taking responsibility for the hemophilia development organization.

James N. Topper Not to Seek for Re-Election to the Board of Amicus Therapeutics

On April 9, 2015, James N. Topper, M.D., Ph.D. informed the board of directors of Amicus Therapeutics, Inc. that he will not seek re-election to the Board when his term expires at the company's upcoming 2015 Annual Meeting of Stockholders.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOLD:US $10.76 USD +0.32

FOLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FOLD.
View Industry Companies
 

Industry Analysis

FOLD

Industry Average

Valuation FOLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 741.7x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 686.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit www.amicustherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.